TITLE

ORTHOVITA COMPLETES RHAKOSS PILOT CLINICAL STUDY IN EUROPE

PUB. DATE
October 2002
SOURCE
Worldwide Biotech;Oct2002, Vol. 14 Issue 10, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Orthovita Inc. has completed the initial clinical pilot study in Europe for RHAKOSS Synthetic Bone Spinal Implant.
ACCESSION #
7464127

 

Related Articles

  • PRODUCT BRIEFS.  // Medical Device Daily;1/16/2008, Vol. 12 Issue 11, p11 

    This section offers news briefs on the medical device industry. Injections have been completed in the Phase III clinical trial evaluating the Isolagen Therapy for the treatment of nasolabial folds or wrinkles. Approval was received by Olympus America from the U.S. Food and Drug Administration...

  • Orthovita submits 510(k) for vertebral bone augmentation.  // Orthopedics Today;Mar2008, Vol. 28 Issue 3, p109 

    The article reports that Orthovita Inc. has submitted a 510(k) filing to the U.S. Food and Drug Administration (FDA) for the use of its Cortoss Bone Augmentation Material in vertebral augmentation. This filing is based on data collected in three U.S. clinical trials conducted under the...

  • ORTHOVITA GETS NANO-PARTICLE STRUCTURED TECHNOLOGY PATENT.  // Worldwide Biotech;Mar2002, Vol. 14 Issue 3, p6 

    Reports on the patent received by Orthovita Inc. on its nano-structured technology

  • ORTHOVITA'S CORTOSS SYNTHETIC BONE FILLER MORE EFFECTIVE.  // Worldwide Biotech;Mar2003, Vol. 15 Issue 3, p3 

    Focuses on clinical studies which examined the efficacy of CORTOSS Synthetic Cortical Bone Void Filler, a biomaterial designed to replace and reinforce bone in the spine weakened by osteoporosis and metastatic disease, from Orthovita Inc.

  • ORTHOVITA SELLS BIOGRAN DENTAL LINE TO IMPLANT INNOVATIONS.  // Biotech Equipment Update;May2000, p5 

    Focuses on issues related to Orthovita Inc. in Malvern, Pennsylvania. Sale of Biogran dental grafting product line to Implant Innovations Inc.; Use of sale proceeds to enhance working capital for the commercialization of CORTOSS and VITOSS products; Reason for increase in 1999 net losses of...

  • Stockholders aim to block Stryker, Orthovita merger.  // Medical Device Daily;6/2/2011, Vol. 15 Issue 106, p3 

    The article reports on the plan of Orthovita stockholders to stop the 316 million U.S. dollars merger of the company with Stryker, which according to a lawsuit filed by the shareholders breaches the fiduciary duty of Orthovita.

  • AAOS notebook.  // Medical Device Daily;2/18/2011, Vol. 15 Issue 34, p2 

    The article reports that orthologics and biosurgery company Orthovita will launch Vitoss Bioactive Foam-2X Bone Graft Substitute, a non-structural bone void filler for use in the pelvis, extremities and posterolateral spine.

  • Styker completes $316M acquisition of Orthovita.  // Medical Device Daily;6/30/2011, Vol. 15 Issue 121, p2 

    The article announces the acquisition of Orthovita based in Pennsylvania by Michigan-based orthopedic device-maker Stryker.

  • UPDATE: Stryker Acquires Orthovita. Cody, Tamika // Mergers & Acquisitions Report;5/23/2011, Vol. 24 Issue 21, p23 

    The article deals with the acquisition of the common stocks owned by U.S. orthobiologics platform developer Orthovita by medical equipment and device developer Stryker Corp. in May 2011.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics